Xenon Pharmaceuticals (XENE) has released an update.
Xenon Pharmaceuticals has announced significant progress in its azetukalner drug development for epilepsy and major depressive disorder (MDD), with Phase 3 trials advancing and a new generic name approval. The company expects to complete enrollment for its epilepsy treatment trials by early 2025 and is poised to initiate Phase 3 trials for MDD in the latter half of the year. These developments mark important steps toward commercializing azetukalner, which has shown promise in clinical trials.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
